FDA extends PDUFA review target date for BENLYSTA BLA to treat systemic lupus erythematosus

Download PDF Copy

Dec 4 2010

Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application (BLA) for BENLYSTA® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from December 9, 2010 to March 10, 2011.

After the FDA Arthritis Advisory Committee met on November 16, 2010 to consider the BENLYSTA BLA, the FDA requested some additional information from HGS, which has been submitted.

Belimumab is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. HGS and GSK are developing belimumab under a definitive co-development and co-commercialization agreement entered into in 2006.

Source:

Human Genome Sciences, Inc. and GlaxoSmithKline PLC

Posted in: Drug Trial News | Disease/Infection News

Comments (0)

Download PDF Copy

Suggested Reading

Social media food shows like Mukbang are changing how people eat

Fast food’s grip on American diets weakens as younger adults cut back

New gluten test detects hidden wheat in food in under three minutes

Can changing food texture reduce how much we eat? Dutch study investigates

Asthma and multiple allergies raise the risk of failed oral food challenges

Food scientists identify worst additives for longevity: flavours, sweeteners, and colourings top list

Can a short message change how we think about expired food?

Plant-based dog food cuts environmental impact by over 90% vs. red meat

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.